Mandate

The European Investment Bank has signed a EUR 47 million financing agreement with Swedish innovative battery technology company Nilar.

October 05, 2020 Banking and Finance

Vinge has acted as European Investment Bank’s (the EIB) counsel in the financing of the battery technology company Nilar International AB (Nilar).

The financing is supported by the InnovFin Energy Demonstration Projects of the European Commission which is a venture financing instrument designated to support innovative clean energy projects in the fields of e.g. renewable energy and energy storage. The aim of the programme is to bridge the gap from demonstration to commercialisation and thus contribute to the deployment of the next generation of innovative low-carbon energy technologies. A link to EIB’s press release may be found here.

Nilar is the globally leading manufacturer of advanced Hydride® batteries (NiMH) for energy storage. Its solutions offer unique safety benefits and are environment-friendly. With production based on 100 percent renewable energy at the manufacturing plant in Sweden, Nilar is revolutionising energy and power supply technology, and advancing the technique of automated battery production. Read more at Nilar’s website.

Vinge’s team included Johan Larsson, Albert Wållgren, Ludvig Wettergren and Viktor Lennartsson.

 

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026